PHILADELPHIA, Feb. 13, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) (“uniQure” or the “Company”) on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the “Class Period”).
Investor Deadline: Investors who purchased uniQure securities during the Class Period may, no later than April 13, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
uniQure, based in Amsterdam, develops and commercializes gene therapies for patients with severe, often life-threatening diseases, with a focus on Huntington’s disease and other neurological disorders.
According to the Complaint, uniQure misled investors about the effectiveness of its gene therapy candidate AMT-130 and the likelihood of accelerated FDA approval. Defendants touted reductions in cerebrospinal neurofilament light protein (CSF NfL) and asserted that FDA agreement on study endpoints would support a near-term BLA submission. Following these statements, the stock jumped nearly 250% from a closing price of $13.66 per share on September 23, 2025 to a close of $47.50 per share on September 24, 2025.
The suit alleges that investors learned on November 3, 2025 that FDA agreement on the study design was not finalized and the BLA timeline was uncertain. On this news, uniQure’s shares dropped over 49%, from a closing price of $67.69 per share on October 31, 2025 to a close of $34.29 per share on November 3, 2025, the next trading day.
If you are a uniQure investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger Montague
Berger Montague is one of the nation’s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.
For more information or to discuss your rights, please contact:
Andrew Abramowitz
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
